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Abstract
Rhodium metalloinsertors are a unique set of metal complexes that bind specifically to DNA base 
pair mismatches in vitro and kill mismatch repair (MMR)-deficient cells at lower concentrations 
than their MMR-proficient counterparts. A family of metalloinsertors containing rhodium-oxygen 
ligand coordination, termed “Rh–O” metalloinsertors, has been prepared and shown to have a 
significant increase in both overall potency and selectivity towards MMR-deficient cells regardless 
of structural changes in the ancillary ligands. Here we describe DNA-binding and cellular studies 
with the second generation of Rh–O metalloinsertors in which an ancillary ligand is varied in both 
steric bulk and lipophilicity. These complexes, of the form [Rh(L)(chrysi)(PPO)]2+, all include the 
O-containing PPO ligand (PPO = 2-(pyridine-2-yl)propan-2-ol) and the aromatic inserting ligand 
chrysi (5,6-chrysene quinone diimine) but differ in the identity of their ancillary ligand L, where L 
is a phenanthroline or bipyridyl derivative. The Rh–O metalloinsertors in this family all show 
micromolar binding affinities for a 29-mer DNA hairpin containing a single CC mismatch. The 
complexes display comparable lipophilic tendencies and pKa values of 8.1–9.1 for dissociation of 
an imine proton on the chrysi ligand. In cellular proliferation and cytotoxicity assays with MMR-
deficient cells (HCT116O) and MMR-proficient cells (HCT116N), the complexes containing the 
phenanthroline-derived ligands show highly selective cytotoxic preference for the MMR-deficient 
cells at nanomolar concentrations. Using mass spectral analyses, it is shown that the complexes are 
taken into cells through a passive mechanism and exhibit low accumulation in mitochondria, an 
off-target organelle that, when targeted by parent metalloinsertors, can lead to non-selective 
cytotoxicity. Overall, these Rh–O metalloinsertors have distinct and improved behavior compared 
to previous generations of parent metalloinsertors, making them ideal candidates for further 
therapeutic assessment.
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INTRODUCTION
Over the past 70 years, DNA and its associated metabolic processes have proven to be 
fruitful targets for the design of new therapeutic agents.1 Many of the most common FDA-
approved chemotherapeutics work by binding DNA, such as the DNA-crosslinking agent 
cisplatin and the DNA-intercalating agent doxorubicin.2–5 Despite the prevalence of these 
drugs in the clinic, there are many drawbacks to their design and mechanisms of action. In 
many cases, the drugs target a generic DNA structure that is common to both healthy and 
cancerous cells. The incidental targeting of healthy tissue can result in dramatic and often 
dose-limiting side effects, such as emesis and nephrotoxicity.6 To circumvent these off-target 
effects, it is essential to identify new therapeutic targets that are almost exclusively found 
within cancerous tissues and cells.
In our research, we focus on one such target: DNA base pair mismatches. Mismatches occur 
regularly in cells due to polymerase errors or interaction with exogenous compounds.7 In 
healthy cells, these errors are corrected by the mismatch repair (MMR) machinery of the 
cell. However, in many solid tumors or tumors of Lynch syndrome patients, mutations in 
MMR proteins severely down-regulate or completely inactivate repair.8,9 As a result, these 
cancers contain a relative abundance of DNA base pair mismatches compared to healthy 
cells, making mismatches a potential biomarker for selective cancer therapy.
Mismatched base pairs have been targeted through the design of metal complexes, called 
rhodium metalloinsertors, which selectively and non-covalently bind these lesions.10 
Rhodium metalloinsertors contain a sterically expansive aromatic chrysi (5,6-
chrysenequinone diimine) ligand that is capable of π-stacking with DNA bases. Due to 
steric bulk, however, the chrysi ligand is unable to easily intercalate into well-matched DNA, 
and instead primarily interacts with DNA at thermodynamically destabilized sites, such as 
mismatches or abasic sites.11 The ability of a prototypical metalloinsertor, 
[Rh(bpy)2(chrysi)]3+ (bpy = 2,2′-bipyridine), to selectively bind DNA mismatches has been 
verified using both in vitro binding assays and crystallographic studies.12–15 
Crystallographic and NMR studies show that this complex binds DNA mismatches via 
metalloinsertion, a non-covalent binding mode in which the complex inserts into DNA at the 
mismatched site from the minor groove, ejects the mismatched DNA bases, and π-stacks 
with the flanking well-matched base pairs.14 This mismatch-targeting ability has also been 
seen in human cell culture experiments, with metalloinsertors exhibiting enhanced 
cytotoxicity in MMR-deficient cell lines relative to their MMR-proficient counterparts.15,16 
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This result is in stark contrast to most DNA-targeting therapeutics, such as the 
aforementioned cisplatin and doxorubicin, which are selective towards MMR-proficient cell 
lines over MMR-deficient cell lines, leading to the development of resistance in MMR-
deficient tumors following treatment.17,18
Several generations of metalloinsertors have been synthesized since [Rh(bpy)2(chrysi)]3+, 
which has led to the recent discovery of a potent and selective family of rhodium 
metalloinsertors containing a pyridyl-alcohol ligand and unique Rh–O ligand coordination 
(Figure 1).19 This Rh–O ligand coordination is structurally distinct from earlier generations 
of parent metalloinsertors, which contained solely Rh–N coordination.20 Furthermore, these 
Rh–O metalloinsertors were found to have improved potency and selectivity towards MMR-
deficient cancer cells over MMR-proficient cancer cells. Surprisingly, this high potency and 
cell selectivity was seen across a variety of metalloinsertors containing O-coordinated 
ligands that differed significantly in size and structure (spanning methyl, pyridyl, phenyl, 
and hexyl functionalization), suggesting the biological activities of Rh–O metalloinsertors 
are not perturbed by ligand substitution off of the O-containing site.
Here, a family of rhodium metalloinsertors was designed and synthesized as variations of the 
Rh–O metalloinsertor [Rh(phen)(chrysi)(PPO)]2+ (phen = 1,10-phenanthroline). These 
complexes, of the form [Rh(L)(chrysi)(PPO)]2+, all include the O-containing PPO ligand but 
differ in the identity of their ancillary ligand, L, where L= bpy, HDPA (2,2′-
dipyridylamine), 4,7-DMP (4,7-dimethyl-1,10-phenanthroline), 5,6-DMP (5,6-
dimethyl-1,10-phenanthroline), and DIP (4,7-diphenyl-1,10-phenanthroline) (Figure 2). The 
ancillary ligand substitution alters the steric bulk and lipophilicity of these complexes, which 
can ultimately affect DNA-binding properties and biological activity.20,21 Each complex 
described, even the most lipophilic and sterically bulky, shows biological selectivity towards 
MMR-deficient cell lines, further demonstrating that the Rh–O ligand framework is 
amenable to a wide array of functionalization. To better understand the trends in biological 
activity of these complexes, each metalloinsertor was examined for binding affinity to 
mismatched DNA, pKa, lipophilicity, whole cell uptake, and subcellular localization into the 
nucleus and mitochondria. The results indicate that minimizing uptake of the complexes into 
the mitochondria may be a key factor in ensuring high biological selectivity and support that 
these Rh–O complexes exhibit distinct differences in metalloinsertor-DNA binding and cell 
activation compared to parent metalloinsertors.
EXPERIMENTAL METHODS
Materials
Commercially available chemicals were used as received. All reagents and Sephadex ion-
exchange resin were obtained from Sigma-Aldrich with the following exceptions. RhCl3 was 
purchased from Pressure Chemical, Inc. Dowex ion-exchange beads were purchased from 
Acros Organics. Analytical standards for Rb and transition metals were purchased from 
Analytical West and Ultra Scientific, respectively. MTT and ELISA assay kits were obtained 
from Roche. Pierce BCA assay kit and NP40 were purchased from Thermo Scientific. Sep-
pak C18 solid-phase extraction (SPE) cartridges were purchased from Waters Chemical Co. 
Cell culture media and supplements were purchased from Invitrogen. Tissue culture flasks 
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and plates were obtained from Corning. 32P labeled ATP was purchased from Perkin Elmer. 
UreaGel supplies were purchased from National Diagnostics. Microbiospin columns were 
purchased from BioRad.
Synthesis and Characterization of Metal Complexes
[Rh(phen)(chrysi)(PPO)]Cl2 and [Rh(bpy)2(chrysi)]Cl3 were synthesized following the 
published protocols.19,22 New metal complexes were synthesized in a similar manner to 
published procedures.19,20,23 A description of the general synthetic procedures are below. 
Complete synthetic details for each complex, including specific amounts (masses, volumes, 
and ratios) as well as slight deviations from the synthetic scheme below, can be found in the 
SI.
Synthesis of [Rh(L)Cl4][K or H3O] complexes
For L = bpy, 4,7-DMP, 5,6-DMP, and DIP: RhCl3•3H2O (1 equiv.) and KCl (1 equiv.) were 
refluxed in methanol for 2 h at 98 °C. Ligand (L, 1 equiv.) was added in a minimum volume 
of methanol and refluxed for 4 h, during which the deep red solution turned to golden-brown 
precipitate. The solution was filtered over a medium fritted filter, rinsed with methanol, and 
dried under vacuum to produce [Rh(L)Cl4]K. Crude yield: 84% (bpy), 86% (4,7-DMP), 91% 
(5,6-DMP), 95% (DIP). For L = HDPA: RhCl3•3H2O (1 equiv.) was refluxed in 
concentrated HCl (38% w/v) for 3 h at 98 °C. Ligand (L, 2 equiv.) was added in a minimum 
volume of HCl, followed immediately by boiling water. The solution was refluxed for 16 h, 
then cooled to 4 °C. The golden precipitate was filtered over a Buchner funnel and dried 
under vacuum to produce [Rh(L)Cl4][H3O]. Crude yield: 100% (HDPA).
Synthesis of [Rh(L)(NH3)4][OTf]3
[Rh(L)Cl4][K or H3O] (1 equiv.) was added to an oven-dried 25 mL Schlenk flask and 
degassed under argon. Neat triflic acid (HOTf, 10 g, excess) was added to the flask under 
positive argon pressure, producing a deep red solution. The flask was purged to remove 
newly formed HCl gas and stirred for 16 h. The solution was then added dropwise to cold, 
stirring ether at −78 °C to produce a yellow-brown precipitate. The precipitate was filtered 
over a medium fritted filter and rinsed with additional cold ether. The product, [Rh(L)
(OTf)4][K or H3O], was combined with NH4OH (28% w/v) and stirred at 40 °C for 1 h. The 
solvent was removed under vacuum and the product was suspended in minimal ethanol, 
precipitated with ether, filtered over a medium fritted filter, and dried further under vacuum 
to produce [Rh(L)(NH3)4][OTf]3. Crude yields of 42% (bpy), 10% (HDPA), 15% (4,7-
DMP), 77% (5,6-DMP), 72% (DIP).
Synthesis of [Rh(L)(chrysi)(NH3)2][OTf]3
[Rh(L)(NH3)4][OTf]3 (1 equiv.) was combined with 5,6-chrysene-quinone (1 equiv.) and a 
mixture of acetonitrile, water, and NaOH, and stirred for 1–12 h at ambient temperature. The 
solution changed from bright orange (the color of free ligand) to red-brown (for L = bpy, 
HDPA, 5,6-DMP, and DIP) or green-brown (for L=4,7-DMP) with no precipitate. The 
reaction was quenched with HCl, producing a deep red solution, and the solvent was 
removed under vacuum. The products from L=bpy, HDPA, and DIP were purified using a 
Boyle and Barton Page 4
J Am Chem Soc. Author manuscript; available in PMC 2018 May 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
C18 SepPak, pre-equilibrated with 0.1% TFA (aq, TFA = trifluoroacetic acid) and eluted 
with 1:3 MeCN:0.1% TFA (aq). The products from L=4,7-DMP and 5,6-DMP were purified 
by HPLC using a reverse phase C18 column with gradient elution from 15:85 MeCN:0.1% 
TFA (aq) to 95:5 MeCN:0.1% TFA (aq) over 30 min. Products were in the form of [Rh(L)
(chrysi)(NH3)2][TFA]3. Crude yields of 33% (bpy), 51% (HDPA), 46% (4,7-DMP), 62% 
(5,6-DMP), 100% (DIP).
Synthesis of [Rh(L)(chrysi)(PPO)]Cl2
[Rh(L)(chrysi)(NH3)2][TFA]3 (1 equiv.) was combined with PPO in a mixture of ethanol 
and water and refluxed 16 h (for L = bpy, 4,7-DMP, 5,6-DMP, and DIP) or 7 days (for 
L=HDPA). The solvent was removed under vacuum and the product was purified by HPLC 
using the method described above for L = bpy, HDPA, 4,7-DMP, and DIP. For L = 5,6-DMP, 
an isocratic method of 30:70 MeCN:0.1% TFA (aq) was used. For L = bpy, HDPA, and 4,7-
DMP, the purified product was converted to the chloride salt using Sephadex QAE resin 
charged with MgCl2. For L = 5,6-DMP and DIP, the purified product was converted to the 
chloride salt using Dowex 1×2 500-100 mesh ion exchange resin. Purified yields of 30% 
(bpy), 10% (HDPA), 10% (4,7-DMP), 23% (5,6-DMP), 33% (DIP).
Characterization of [Rh(bpy)(chrysi)(PPO)](TFA)2
LCQ-MS (cation): m/z calc. 650.1 (M-1H+), 325.6 (M2+); obs. 650.0, 325.8. UV-Vis (H2O): 
259nm (59,800 M−1 cm−1), 287nm (43,100 M−1 cm−1), 298nm (37,100 M−1 cm−1), 312nm 
(32,000 M−1 cm−1), 435nm (10,000 M−1 cm−1). 1H NMR (500 MHz, Acetonitrile-d3) δ 
13.44 (br s, 1.2H), 11.89 (br s, 2H), 9.45 (d, J = 5.6 Hz, 1H), 9.36 (d, J = 5.7 Hz, 0.6H), 8.80 
(d, J = 8.0, 1.4 Hz, 1H), 8.71 (d, J = 5.3 Hz, 0.6H), 8.62 (d, J = 8.2 Hz, 0.6H), 8.60-8.54 (m, 
2.6H), 8.43-8.26 (m, 8H), 8.26-8.21 (m, 1H), 8.14 (d, J = 8.2, 1.5 Hz, 0.6H), 8.06-7.89 (m, 
4.8H), 7.85-7.78 (m, 1,6H), 7.77-7.68 (m, 3.2H), 7.68-7.61 (m, 2.2H), 7.60-7.52 (m, 2.6H), 
7.31 (d, 0.6H), 7.29-7.21 (m, 2.6H), 1.91 (s, 3H), 1.87 (s, 1.8H), 1.58 (s, 4.8H), purified as a 
1:0.6 mixture of diastereomers.
Characterization of [Rh(HDPA)(chrysi)(PPO)](TFA)2
LCQ-MS (cation): m/z calc. 665.2 (M-1H+), 333.1 (M2+); obs. 665.3, 333.3. UV-Vis (H2O): 
259nm (60,400 M−1 cm−1), 283nm (45,900 M−1 cm−1), 326nm (18,600 M−1 cm−1), 440nm 
(8,500 M−1 cm−1). 1H NMR (500 MHz, Acetonitrile-d3) δ 12.49 (br s, 1H), 12.04 (br s, 
1H), 8.72 (dd, J = 8.0, 1.3 Hz, 1H), 8.50 (d, J = 6.0 Hz, 1H), 8.38-8.31 (m, 3H), 8.31-8.23 
(m, 2H), 8.20-8.13 (m, 2H), 8.08-8.00 (m, 2H), 7.98 (td, J = 8.6, 1.6 Hz, 1H), 7.94-7.81 (m, 
4H), 7.69 (m, 3H), 7.51 (ddd, J = 7.6, 6.0, 1.4 Hz, 1H), 7.23 (ddd, J = 7.4, 6.1, 1.3 Hz, 1H), 
7.17 (ddd, J = 7.4, 6.2, 1.4 Hz, 1H), 1.78 (s, 3H), 1.56 (s, 3H), purified as a single 
diastereomer.
Characterization of [Rh(4,7-DMP)(chrysi)(PPO)](TFA)2
LCQ-MS (cation): m/z calc. 702.2 (M-1H+), 351.6 (M2+); obs. 702,3, 351.8. UV-Vis (H2O): 
269nm (106,800 M−1 cm−1), 440nm (11,400 M−1 cm−1). 1H NMR (500 MHz, Acetonitrile-
d3) δ 13.31 (br s, 0.8H), 11.75 (br s, 2H), 9.50 (d, J = 5.4 Hz, 1H), 9.42 (d, J = 5.4 Hz, 
0.4H), 8.86 (dd, J = 5.5, 0.9 Hz, 1H), 8.83 (dd, J = 8.0, 1.3 Hz, 1H), 8.73 (d, J = 5.4 Hz, 
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0.4H), 8.47 (d, J = 2.5 Hz, 0.4H), 8.46-8.35 (m, 4.2H), 8.34 (d, J = 8.2 Hz, 0.4H), 8.27 (d, J 
= 8.8 Hz, 1H), 8.21-8.17 (m, 1.4H), 8.16 (d, J = 8.1 Hz, 0.4H), 8.08 (dd, J = 5.4, 1.0 Hz, 
1H), 8.04 (d, J = 5.4 Hz, 0.4H), 8.00 (dd, J = 7.5, 1.7 Hz, 1H), 7.97-7.92 (m, 2.4H), 7.84 (m, 
1.8H), 7.77 (m, 1.4H), 7.61-7.51 (m, 5.2H), 7.19-7.15 (m, 0.4H), 7.10-7.03 (m, 2.8H), 3.05 
(s, 3H), 3.04 (s, 1.2H), 3.02 (s, 1.2H), 2.99 (s, 3H), 1.95 (s, 3H), 1.92 (s, 1.2H), 1.62 (s, 3H), 
1.61 (s, 1.2H), purified as a 1:0.4 mixture of diastereomers.
Characterization of [Rh(5,6-DMP)(chrysi)(PPO)](TFA)2
LCQ-MS (cation): m/z calc. 702.2 (M-1H+), 351.6 (M2+); obs. 702.3, 351.8. UV-Vis (H2O): 
267nm (80,600 M−1 cm−1), 280nm (81,700 M−1 cm−1), 438nm (10,500 M−1 cm−1). 1H 
NMR (500 MHz, Acetonitrile- d3) δ 13.40 (br s, 0.3H), 11.77 (br s, 1H), 9.68 (d, J = 5.2 Hz, 
1H), 9.59 (d, J = 5.1 Hz, 0.3H), 9.06-8.97 (m, 3.9H), 8.84-8.89 (m, 1.3H), 8.43-8.37 (m, 
2.6H), 8.34 (d, J = 8.2 Hz, 0.3H), 8.29-8.14 (m, 5.2H), 8.02-7.97 (m, 2.3H), 7.96-7.89 (m, 
2.6H), 7.83-7.73 (m, 1.6H), 7.57 (td, J = 7.4, 1.4 Hz, 2H), 7.55-7.50 (m, 1H), 7.17 (d, J = 5.7 
Hz, 0.3H), 7.10-7.02 (m, 2.3H), 2.91 (s, 0.9H), 2.90 (s, 0.9H), 2.89 (s, 3H), 2.87 (s, 3H), 
1.93 (s, 3H), 1.90 (s, 0.9H), 1.58 (s, 3.9H), purified as a 1:0.3 mixture of diastereomers.
Characterization of [Rh(DIP)(chrysi)(PPO)]Cl2
LCQ-MS (cation): m/z calc. 826.2 (M-1H+); obs. 826.3. UV-Vis (H2O): 267nm (103,000 M
−1
 cm−1). 1H NMR (500 MHz, Methanol-d4) δ 9.74 (dd, J = 5.5, 0.9 Hz, 1H), 9.70 (dd, J = 
5.5, 0.8 Hz, 0.5H), 8.89 (m, 1.5H), 8.76 (m, 1.5H), 8.58-8.46 (m, 4.5H), 8.40-8.28 (m, 6H), 
8.14-7.98 (m, 4.5H), 7.81-7.59 (m, 15H), 7.56-7.49 (m, 1.5H), 7.41-7.33 (m, 6H), 7.34-7.23 
(m, 3H), 2.07 (s, 3H), 2.02 (s, 1.5H), 1.70 (s, 1.5H), 1.69 (s, 3H), purified as a 1:0.5 mixture 
of diastereomers.
Enantiomeric Separation of [Rh(phen)(chrysi)(PPO)]Cl2
Purified [Rh(phen)(chrysi)(PPO)][TFA]2 was dissolved in 1:1 ethanol:water and HPLC 
purified on an Astec CYCLOBOND chiral column using an isocratic elution method of 
40:60 ACN:0.1 M KPF6 (aq) over 37 min. The column was periodically rinsed with 40:60 
MeCN:H2O to remove KPF6 buildup. Separated enantiomers were collected and exchanged 
to the chloride salt using Sephadex QAE resin pre-equilibrated with MgCl2. The 
enantiomeric nature of the collected fractions was verified using circular dichroism (CD) as 
follows: 200 μM solutions of Δ- and Λ-[Rh(phen)(chrysi)(PPO)]Cl2 were made in aqueous 
solution and their CD spectra recorded in 1 nm increments on an Aviv 62DS 
spectropolarimeter under a N2 atmosphere at ambient temperature. The spectra were 
recorded a second time 30 d later to assess decomposition or racemization of the sample, 
and none was observed.
Determination of Extinction Coefficients
Aqueous solutions of each [Rh(L)(chrysi)(PPO)]Cl2 complex were made and a UV-Visible 
spectrum was recorded for each. The solutions were diluted 50x, 100x, 500x, and 1000x in 
2% HNO3. The dilutions were analyzed for Rh content via ICP-MS (inductively coupled 
plasma mass spectrometry) and the concentration was determined by comparison to a 
standard curve. Extinction coefficients were determined from the UV-Visible absorbance 
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measurement of the initial solution and the Rh concentration of the dilutions following 
Beer’s law (A=εlc). L = DIP was observed to significantly adsorb onto plastics, therefore 
PTFE (polytetrafluoroethylene) and PFA (perfluoroalkoxy alkane) coated materials were 
used in the workup and analysis of its extinction coefficient.
Partition Coefficient Determination
One-octanol and 10 mM Tris-HCl, pH 7.4 were pre-equilibrated with each other by 
vigorously shaking the phases together. A solution of each metalloinsertor was made in 
octanol and the UV-Visible spectrum of the solution recorded. Each solution was combined 
with an equal volume of aqueous buffer and shaken using a foam insert on a Vortex-Genie 2 
running at maximum speed for 16 h. The samples were centrifuged to separate the aqueous 
and octanol phases and a UV-Visible spectrum of each octanol fraction was recorded. The 
baseline value obtained at 800 nm was used to normalize the spectra to a common zero 
point. The absorbance of the ~260 nm peak in the final spectrum was compared to the initial 
spectrum to determine the partition coefficient following the literature.24 The partition 
coefficients from three experiments were measured for each [Rh(L)(chrysi)(PPO)]Cl2 
complex and averaged to give the partition coefficient.
pKa Determination of Metalloinsertors
A ~25 μM solution of each metalloinsertor was made in 100 mM NaCl. The pH of the 
sample was adjusted to 4.5 using HCl (10 mM). NaOH (10 mM) was titrated into the 
solution, with stirring. The pH and UV-Visible spectrum were recorded after each base 
addition, up to a pH of 10.5. A back titration to pH 6 was performed to check for 
decomposition, and none was observed. Spectra were corrected for baseline and volume 
changes. The absorbance of the ~430 nm peak was plotted against pH and fit to a sigmoidal 
curve in OriginPro v8.5, and the pKa was determined as the inflection point of the curve. 
Three pKa titrations were performed for each [Rh(L)(chrysi)(PPO)]Cl2 complex and 
averaged to give an average pKa value.
Binding Constant Determination
A DNA hairpin (5′-GGCAGGXATGGCTTTTTGCCATYCCTGCC-3′, where XY=CG or 
CC for a well-matched or mismatched hairpin, respectively) was radiolabeled with γ-32P 
ATP and prepared following the literature.10,19,22 Full details of DNA preparation and 
purification can be found in the SI. A 4 μM solution of the photocleaving metalloinsertor 
[Rh(bpy)2(chrysi)]Cl3 and solutions containing 0–400 μM of a competing metalloinsertor, 
[Rh(L)(chrysi)(PPO)]Cl2 (which does not photocleave DNA), were made in MilliQ water. 
Five μL of the [Rh(bpy)2(chrysi)]Cl3 solution, 5 μL of the competing metalloinsertor, and 10 
μL of the hairpin DNA were combined to create a solution containing 1 μM 
[Rh(bpy)2(chrysi)]Cl3, 0–100 μM competing metalloinsertor, and 1 μM DNA. The samples 
were irradiated with an Oriel 1000 W Hg/Xe solar simulator (340–440 nm) for 20 min. After 
irradiation, solvent was removed from the samples and the samples were counted on a 
scintillation counter to determine the necessary exposure time (with 300,000 cpm needing a 
1 hour exposure) and they were suspended in a denaturing formamide loading dye. Samples 
were electrophoresed on a 20% denaturing polyacrylamide urea gel.
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A phosphor screen was exposed to the polyacrylamide gel and imaged using a Typhoon FLA 
9000 biomolecular imager. The ratio of photocleaved to uncleaved DNA was quantified 
using ImageQuant TL software. The ratio was plotted against the concentration of [Rh(L)
(chrysi)(PPO)]Cl2 and fit to a sigmoidal curve in OriginPro v8.5 to determine the inflection 
point of the fit. The binding affinity of the competing metalloinsertor was calculated in 
Mathematica 9.0 by solving simultaneous equilibria involving DNA, [Rh(bpy)2(chrysi)]Cl3, 
and [Rh(L)(chrysi)(PPO)]Cl2. Three photocleavage titrations were performed for each 
[Rh(L)(chrysi)(PPO)]Cl2 complex and averaged to give the binding affinity.
Melting Temperature Analysis
Melting temperature analysis was performed on a Beckman DU 7400 spectrophotometer 
equipped with a Tm Analysis Accessory. The short oligomer, 5′-CGGACTCCG-3′ 
(underline denotes mismatch), was purchased from IDT DNA and purified by HPLC. 
Samples containing 11 μM ssDNA (ultimately 5.5 μM dsDNA and mismatches) and 6 μM of 
[Rh(phen)(chrysi)(PPO)]Cl2, [Rh(bpy)2(chrysi)]Cl3 or no metal complex were prepared in 
phosphate buffer (5 mM phosphate, 50 mM NaCl, pH 7.0). Samples were heated at a rate of 
0.5 °C/min and absorbance was measured at 260 nm every 0.5 °C between 10 °C and 50 °C. 
Data from three experiments was combined and fit to a sigmoidal curve in OriginPro v8.5 
and the Tm was taken as the inflection point of the curve.
Cell Culture
HCT116N and HCT116O cells were grown in RPMI (Roswell Park Memorial Institute) 
1640 media supplemented with 10% FBS (fetal bovine serum), 2 mM L-glutamine, 0.1 mM 
non-essential amino acids, 1 mM sodium pyruvate, 100 units/mL penicillin and 
streptomycin, and 100 μg/mL Geneticin (G418). The cells were incubated in tissue culture 
flasks or plates at 37 °C in a 5% CO2 atmosphere. All cell studies were performed with the 
chloride salt of each metalloinsertor.
Cell Proliferation ELISA
Cell proliferation ELISA (enzyme-linked immunosorbent assay) was performed following 
the manufacturers instructions. Briefly, 2×103 HCT116N or HCT116O cells in 100 μL 
media were plated into each well of a 96-well plate. The cells were allowed to adhere for 24 
h before the addition of 100 μL of media containing various concentrations of rhodium 
metalloinsertor. The plates were incubated for an additional 48 h before the rhodium-
containing media was replaced with fresh media, with which the cells were allowed to grow 
for the remainder of a 72 h period. Cells were then treated with an excess of the unnatural 
nucleic acid, BrdU (bromodeoxyuridine), for 24 h during which time it could be 
incorporated into newly synthesized DNA. Cells were then fixed, labeled with a BrdU 
antibody, and quantified using a colorimetric substrate solution and stop solution. 
Absorbance was measured at 450 nm (background subtracted at 690 nm). Decrease in 
cellular proliferation was determined for each metalloinsertor concentration through 
comparison to untreated cells. Outliers were removed using a modified Thompson Tau test. 
An additional variation of this assay was performed in which the cells were treated with 
rhodium metalloinsertor for 24 h, then directly treated with BrdU in fresh media.
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MTT Cytotoxicity Assay
Cell proliferation MTT (MTT = 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltatrazolium 
bromide) assays were performed following the manufacturers instructions. Briefly, 5×104 
HCT116N or HCT116O cells in 100 μL media were plated into each well of a 96-well plate. 
Various concentrations of a rhodium metalloinsertor were added to each well. The cells were 
allowed to incubate for 72 h before treatment with MTT for 4 h, during which time MTT 
could be converted into formazan by metabolically active cells. The formazan crystals were 
solubilized and quantified by absorbance at 570 nm (background subtracted at 690 nm). 
Viability was determined for each metalloinsertor concentration through comparison to 
untreated cells. Outliers were removed using a modified Thompson Tau test. An additional 
variation of this assay was performed in which the cells were allowed to adhere to the 96-
well plate overnight before treated with rhodium metalloinsertor for 24 h, followed by MTT 
treatment.
Uptake and Localization Experiments
Whole-cell uptake, mitochondrial localization, and nuclear localization of metalloinsertors 
were determined following published methods.25 Prior to whole-cell, mitochondrial, and 
nuclear rhodium determination, 24-hour ELISA and MTT assays were performed to 
determine a metalloinsertor concentration that would not result in significant cell death by 
MTT but showed some anti-proliferative effect by ELISA. The concentrations used in the 
uptake and localization studies of the [Rh(L)(chrysi)(PPO)]Cl2 family were 0.2 μM for 
L=DIP, 0.5 μM for L=phen, bpy, HDPA, 4,7-DMP, and 5,6-DMP, and 10 μM for 
[Rh(bpy)2(chrysi)]Cl3, which was included as a control.
Assay for Whole-Cell Rhodium Concentration
Whole-cell uptake experiments were performed following published protocols.20 Briefly, 
1×106 HCT116N or HCT116O cells were plated into 6-well tissue culture treated plates and 
allowed to adhere for 24 h. Media was aspirated from the cells and fresh media containing a 
metalloinsertor was added to each well. Cells were allowed to incubate for an additional 
0.5–24 h with the Rh-containing media. After incubation, media was aspirated and the cells 
were rinsed with PBS (phosphate buffered saline, pH 7.4) to remove surface rhodium. Cells 
were lysed directly in the well using 1 mL of 1% SDS solution. These samples were 
transferred to microcentrifuge tubes and sonicated for 10 s at 20% amplitude on a Qsonica 
Ultrasonic sonicator. Cell lysate was combined with an equal volume 2% HNO3. This 
solution was analyzed for Rh content on an Agilent 8800 Triple Quadrupole ICP-MS and the 
concentration of Rh in each sample was determined by comparison to a standard curve 
(ranging from 1–100 ppb Rh) and normalized using the protein content of each sample. The 
protein content of each sample was determined using a Pierce BCA assay, following the 
manufacturer’s instructions.
Assay for Mitochondrial Rhodium Concentration
Mitochondrial uptake experiments were performed following published protocols.20,26 
Briefly, 1.5×107 HCT116N and HCT116O cells were plated in T75 tissue culture treated 
flasks. The cells were allowed to adhere for 24 h, after which media was aspirated from each 
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flask and restored with 20 mL media containing a rhodium metalloinsertor. The cells were 
allowed to grow in the presence of Rh-containing media for 24 h, then harvested using 
0.05% trypsin over 5 minutes. Cells were pelleted by centrifugation at 1200 rpm for 5 min. 
The pellet was rinsed and suspended in PBS, then pelleted again and the PBS removed. The 
cell pellet was suspended in 500 μL mitochondrial extraction buffer (200 mM mannitol, 68 
mM sucrose, 50 mM PIPES, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM DTT added 
just before use, and protease inhibitors added just before use) and incubated on ice for 20 
min. Each sample was homogenized by 35 passes thorough a 21-gauge needle and syringe. 
The resultant solution was centrifuged for 5 min at 750 rpm. The supernatant of each sample 
was transferred to a 1.5 mL microcentrifuge tube and centrifuged for 10 min at 14,000 g. 
The supernatant was decanted and the resulting pellet was the mitochondrial fraction. SDS 
(800 μL of a 1% solution) was added to the pellet and sonicated for 10 s at 40% amplitude 
on a Qsonica Ultrasonic sonicator. Mitochondrial lysate was combined with an equal volume 
of 2% nitric acid. This solution was analyzed for Rh content on an Agilent 8800 Triple 
Quadrupole ICP-MS and the concentration of Rh in each sample was determined by 
comparison to a standard curve (ranging from 1–100 ppb Rh) and normalized using the 
protein content of each sample. The protein content of each sample was determined using a 
Pierce BCA assay, following the manufacturer’s instructions.
Assay for Nuclear Rhodium Concentration
Nuclear uptake experiments were performed following published protocols.20 Briefly, 1×107 
HCT116N and HCT116O cells were plated in T75 tissue culture treated flasks. The cells 
were allowed to adhere for 24 h before the media was aspirated and restored with 20 mL 
media containing a rhodium metalloinsertor. The cells were allowed to grow in the presence 
of Rh-containing media for 24 h, then harvested using 0.05% trypsin over 5 minutes. Cells 
were pelleted by centrifugation at 1200 rpm for 5 min. The pellet was rinsed and suspended 
in PBS, then pelleted and the PBS removed. Each cell pellet was suspended in 1 mL 
hypotonic buffer (20 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2), transferred to a 
microcentrifuge tube, and incubated on ice for 15 min. NP-40 (50 μL of a 10% solution) was 
added to each sample, vortexed for 10 s at the highest setting, and centrifuged at 3000 g for 
10 min. The supernatant was decanted and the resulting pellet was the nuclear fraction. SDS 
(800 μL of a 1% solution) was added to the pellet and then sonicated for 10 s at 40% 
amplitude on a Qsonica Ultrasonic sonicator. Nuclear lysate was combined with an equal 
volume of 2% HNO3. This solution was analyzed for Rh content on an Agilent 8800 Triple 
Quadrupole ICP-MS and the concentration of Rh in each sample was determined by 
comparison to a standard curve (ranging from 1–100 ppb Rh) and normalized using the 
protein content of each sample. The protein content of each sample was determined using a 
Pierce BCA assay, following the manufacturer’s instructions.
Assay for Uptake of Metalloinsertors
Mechanism of uptake experiments were adapted from published protocols.27 RbCl and 
[Ru(DIP)(dppz)]Cl2 were used as positive and negative controls, respectively. Briefly, 1×106 
HCT116N or HCT116O cells were plated into 6-well tissue culture treated plates and 
allowed to adhere for 24 h. Metabolic inhibitors (5 μM oligomycin in ethanol and 50 mM 2-
deoxy-D-glucose) or control solutions (5 mM glucose and ethanol) were added to the cell 
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culture media and samples were incubated for 1 h. Media was removed by aspiration and 
each well was washed with PBS. Media (3 mL) containing the Rh–O metalloinsertor 
[Rh(phen)(chrysi)(PPO)]Cl2 (0.5 μM), the parent metalloinsertor [Rh(bpy)2(chrysi)]Cl3 (10 
μM), [Ru(DIP)(dppz)]Cl2 (2 μM), or RbCl (25 μM) was then added to each well and 
incubated for 1 h. Media was aspirated and cells were rinsed with PBS to remove surface 
rhodium, ruthenium, or rubidium. Cells were lysed directly in the well using 1 mL of 1% 
SDS solution. Samples were transferred to microcentrifuge tubes and sonicated for 10 s at 
20% amplitude on a Qsonica Ultrasonic sonicator. Cell lysate was combined with an equal 
volume of 2% HNO3 and analyzed for Rh, Ru, and Rb content on an Agilent 8800 Triple 
Quadrupole ICP-MS, and the concentration of Rh, Ru, or Rb in each sample was determined 
by comparison to a standard curve (ranging from 1–100 ppb) and normalized using the 
protein content of each sample. The protein content of each sample was determined using a 
Pierce BCA assay, following the manufacturer’s instructions.
RESULTS
Establishing the Enantiomeric Activity of [Rh(phen)(chrysi)(PPO)]2+
Enantiomeric separation was performed for the complex [Rh(phen)(chrysi)(PPO)]2+ to 
establish the interaction of its Δ- and Λ-enantiomers with DNA in vitro and in MMR-
deficient or -proficient cells in culture. The Δ- and Λ- enantiomers of [Rh(phen)(chrysi)
(PPO)]2+ were isolated with >90% and >95% enantiomeric excess, respectively 
(Supplementary Figure S1). Circular dichroism experiments confirmed the enantiomeric 
nature of the isolated complexes, and no racemization was observed at ambient temperature 
over 1 month (Supplementary Figure S1). Competition titrations between [Rh(phen)(chrysi)
(PPO)]2+ and the photocleaving metalloinsertor [Rh(bpy)2(chrysi)]3+ in the presence of 32P-
radiolabeled DNA containing a CC mismatch revealed both enantiomers are capable of 
binding mismatched DNA base pairs with similar affinity (106 M−1, Table 1).10 
Furthermore, both enantiomers were found to have selective cytotoxic effects towards 
MMR-deficient cells over MMR-proficient cells in MTT experiments (Supplementary 
Figure S2). These studies confirm that both enantiomers of the PPO-containing 
metalloinsertor, [Rh(phen)(chrysi)(PPO)]2+, exhibit binding properties towards mismatched 
DNA that are consistent with a previous generation of Rh–O metalloinsertors. These Rh–O 
complexes show no enantiomeric preference in binding DNA, unlike parent metalloinsertors, 
which show a high enantiomeric preference for the Δ-isomer in binding DNA.15,19
Binding of Metalloinsertors to a Single Base Pair Mismatch
The binding affinities of [Rh(L)(chrysi)(PPO)]2+ metalloinsertors to DNA containing a 
single CC mismatch were determined. The [Rh(L)(chrysi)(PPO)]2+ complexes do not 
photocleave DNA upon irradiation, so their binding affinities were assayed via a competition 
titration with [Rh(bpy)2(chrysi)]3+, a complex known to photocleave DNA selectively upon 
mismatch binding and irradiation.22 A CC mismatch was used as it is highly destabilized 
relative to other mismatches and therefore undergoes significant photocleavage in the 
presence of [Rh(bpy)2(chrysi)]3+. A constant concentration of [Rh(bpy)2(chrysi)]3+ and 
varying concentrations of the competing [Rh(L)(chrysi)(PPO)]2+ metalloinsertor were 
incubated with a DNA hairpin containing a single CC mismatch, irradiated, and the DNA 
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photocleavage products were separated on a denaturing gel. The ratio of photocleaved DNA 
to intact DNA was plotted against the log of the rhodium concentration and fit to a sigmoidal 
curve (Figure S3). The inflection point of the sigmoidal fit was used to determine the 
binding affinity of the competing [Rh(L)(chrysi)(PPO)]2+ metalloinsertor by solving 
simultaneous equilibria equations using the known binding affinity of [Rh(bpy)2(chrysi)]3+. 
The binding affinities of these complexes are shown in Table 1. All complexes were tested as 
racemic mixtures and exhibit binding affinities in the range of 2.4 to 7.2 × 106 M−1 (Table 
1). Despite differences in ligand steric bulk, all Rh–O metalloinsertors tested have binding 
affinities within one order of magnitude of each other, and thus bind DNA with comparable 
affinity.
Binding was assessed further via melting temperature analysis. A short, palindromic DNA 
sequence containing a central CC mismatch was incubated in the presence of the parent 
metalloinsertor, [Rh(bpy)2(chrysi)]Cl3, or the Rh–O metalloinsertor, [Rh(phen)(chrysi)
(PPO)]Cl2. The chosen DNA sequence has a low Tm and therefore exists as ssDNA at room 
temperature.13 In the presence of metalloinsertor, however, the DNA anneals and the melting 
temperature increases dramatically to 44.9 ± 0.6 and 41.3 ± 0.5 °C for [Rh(bpy)2(chrysi)]Cl3 
and [Rh(phen)(chrysi)(PPO)]Cl2, respectively (Supplementary Figure S3B). These results 
are in good agreement with the results of the DNA binding assay describe above and 
corroborate the result that parent and Rh–O metalloinsertors have comparable binding 
affinities to mismatches in DNA, with [Rh(phen)(chrysi)(PPO)]Cl2 stabilizing DNA to a 
slightly lesser extent than [Rh(bpy)2(chrysi)]Cl3.
pKa Determination of Metalloinsertors
The pKa values of [Rh(L)(chrysi)(PPO)]2+ metalloinsertors were assessed via spectroscopic 
pH titrations (Table 1, Supplementary Figures S4–S8). The absorbance of a 435–440 nm 
peak, which corresponds to a charge transfer located on the chrysi ligand, was plotted 
against the pH of the solution for each complex.28 Data were fit to a sigmoidal curve and the 
inflection point was taken as the pKa of the complex, specifically of the imine proton on the 
chrysi ligand. All Rh–O metalloinsertors exhibited pKa values in the range of 8.1 to 9.1, 
which are above physiological pH (Table 1), indicating that the chrysi ligands of these 
complexes remain protonated in cell culture media or within cells. It has been shown 
previously that fully protonated chrysi ligands, which are seen with Rh–O metalloinsertors, 
buckle in contrast to the deprotonated chrysi ligands of the parent metalloinsertors, which 
are completely flat and thus easy to stack with the DNA base pairs once inserted.19
Partition Coefficient and Lipophilicity of Metalloinsertors
The [Rh(L)(chrysi)(PPO)]Cl2 family of metalloinsertors was designed to vary in 
lipophilicity, and the partition coefficients of each [Rh(L)(chrysi)(PPO)]2+ metalloinsertor 
were determined between aqueous buffer (10 mM Tris-HCl, pH 7.4) and 1-octanol 
according to literature methods.24 Absorbance measurements at the ~260 nm peak were 
made in the 1-octanol phase before and after equilibration with the aqueous phase. These 
absorbance values were compared to determine the partition coefficient, log P (Table 1, 
Supplementary Figures S9–S12). The log P values followed the expected trend with the least 
bulky complexes ([Rh(bpy)(chrysi)(PPO)]2+ and [Rh(HDPA)(chrysi)(PPO)]2+) having the 
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lowest log P values and the bulkiest complex ([Rh(DIP)(chrysi)(PPO)]2+) having the 
greatest log P value. Surprisingly, despite their cationic nature, under these conditions the 
[Rh(L)(chrysi)(PPO)]2+ metalloinsertors are all lipophilic and have partition coefficients 
favoring octanol over water, ranging from 0.68 to >2.0.
Cytotoxic and Anti-Proliferative Effects in MMR-Deficient and -Proficient Cells
The ability of metalloinsertors to selectively kill or impair growth of MMR-deficient cells is 
a critical factor in their potential value as chemotherapeutic agents.19,29 In this structure-
activity relationship study, we used ELISA and MTT assays to determine the effect of ligand 
substitution on biological activity in MMR-deficient and -proficient cells. The ELISA was 
used to determine the inhibitory effects on DNA synthesis and the MTT assay was 
performed to establish levels of cytotoxicity. For the ELISA, each metalloinsertor was 
incubated with HCT116N (MMR-proficient) or HCT116O (MMR-deficient) cells at various 
concentrations before treatment with the unnatural nucleic acid BrdU. Colorimetric antibody 
treatment allowed the relative BrdU incorporation into DNA to be quantified, and cellular 
proliferation was then determined as the ratio of BrdU incorporation between 
metalloinsertor-treated cells and untreated control cells. The results of the 48-hour 
metalloinsertor treatment are shown in Figure 3, and the results of a 24-hour treatment are 
shown in Supplemental Figure S15. All [Rh(L)(chrysi)(PPO)]2+ metalloinsertors exhibit 
anti-proliferative activity with selectivity towards the MMR-deficient cell line. The 
maximum proliferation difference (referred to as selectivity) between the cell lines and the 
concentration at which this selectivity occurs (referred to as potency) are as follows: 77 
± 10% at 400 nM for [Rh(phen)(chrysi)(PPO)]2+, 78 ± 18% at 2 μM for [Rh(bpy)(chrysi)
(PPO)]2+, 47 ± 10% at 25 μM for [Rh(HDPA)(chrysi)(PPO)]2+, 66 ± 6% at 400 nM for 
[Rh(4,7-DMP)(chrysi)(PPO)]2+, 67 ± 5% at 400 nM for [Rh(5,6-DMP)(chrysi)(PPO)]2+, 
and 70 ± 23% at 160 nM for [Rh(DIP)(chrysi)(PPO)]2+.
For the MTT assay, each metalloinsertor was incubated with HCT116N (MMR-proficient) 
or HCT116O (MMR-deficient) cells at various concentrations before the addition of MTT, 
which can be converted into formazan by mitochondrial reductase activity in a functioning 
cell. Colorimetric measurements of formazan allow the relative viability to be quantified, 
and cellular viability is then determined as the ratio of formazan produced between 
metalloinsertor-treated cells and untreated control cells. The results of the 72-hour treatment 
are shown in Figure 4 and the results of the 24-hour treatment are shown in Supplemental 
Figure S16. All [Rh(L)(chrysi)(PPO)]2+ metalloinsertors exhibit cytotoxic activity with 
selectivity towards the MMR-deficient cell line. The maximum proliferation difference 
between the cell lines and the concentration at which this difference occurs are as follows: 
52 ± 5% at 300 nM for [Rh(phen)(chrysi)(PPO)]2+, 30 ± 7% at 2 μM for [Rh(bpy)(chrysi)
(PPO)]2+, 13 ± 11% at 32 μM for [Rh(HDPA)(chrysi)(PPO)]2+, 46 ± 8% at 600 nM for 
[Rh(4,7-DMP)(chrysi)(PPO)]2+, 49 ± 3% at 600 nM for [Rh(5,6-DMP)(chrysi)(PPO)]2+, 
and 39 ± 6% at 640 nM for [Rh(DIP)(chrysi)(PPO)]2+.
Whole-Cell Uptake, Mechanism of Uptake, and Organelle Localization
To better understand the range of biological activities of these complexes, cellular uptake 
and mechanism of uptake were examined via ICP-MS based assays. 24-hour ELISA and 
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MTT assays were performed to determine a suitable concentration for uptake and 
localization studies (which were performed over a 24-hour timescale). To minimize cell 
death in this assay, a factor which can complicate data interpretation, suitable dosing was 
determined to be at a concentration at which there was noticeable anti-proliferative effects in 
the HCT116O cells via ELISA but no significant cytotoxicity via MTT assay. Whole cell 
uptake studies were performed with each [Rh(L)(chrysi)(PPO)]2+ complex at 0.5 μM with 
the exception of [Rh(DIP)(chrysi)(PPO)]2+, which was performed at 0.2 μM due to its high 
cytotoxicity at 0.5 μM. For whole cell uptake studies, cells were incubated with 
metalloinsertors for 24 h before they were lysed and analyzed for rhodium content via ICP-
MS, with rhodium concentrations normalized to the protein content of each sample. The 
whole cell uptakes of each metalloinsertor in HCT116O cells are shown in Figure 5 (results 
in HCT116N cells are similar and shown in Supplementary Figure S17). Overall, all [Rh(L)
(chrysi)(PPO)]2+ complexes exhibit uptake into cells at concentrations within one order of 
magnitude of each other. The uptake of these complexes correlates generally with their 
lipophilicity values, with the least lipophilic complexes ([Rh(HDPA)(chrysi)(PPO)]2+ and 
[Rh(bpy)(chrysi)(PPO)]2+) having the poorest uptake and the most lipophilic complex 
([Rh(DIP)(chrysi)(PPO)]2+) having the highest uptake. Lipophilicity has long been 
correlated with an increase in cellular uptake and a resultant increase in drug potency.30,31
In addition to examining whole cell uptake of the [Rh(L)(chrysi)(PPO)]2+ metalloinsertors, 
the uptake over time and the mechanism of uptake were also examined. In the former 
experiment, cells were incubated with a metalloinsertor for 0.5, 1, 3, 6, 9, or 24 h before 
being lysed and analyzed for rhodium content by ICP-MS. The whole-cell uptake over time 
of these metalloinsertors in HCT116O cells is shown in Figure 5 (results in HCT116N cells 
are similar and shown in Supplementary Figure S17). The complexes appear to show 
significant increases in uptake over the first 3–6 h of incubation with cells, followed by 
plateau with no evidence of significant efflux during a 24-hour period. These results are 
consistent with previous studies on metalloinsertors.20
A metabolic inhibition assay was performed to better understand the mechanism of cellular 
uptake of [Rh(L)(chrysi)(PPO)]2+ metalloinsertors. HCT116N and HCT116O cells were 
pre-treated with the metabolic inhibitors oligomycin A, an inhibitor of oxidative 
phosphorylation, and 2-deoxy-D-glucose, an inhibitor of glycolysis.27 Metabolic inhibition 
depletes cellular ATP (adenosine triphosphate), so any compound that is taken into the cell 
via an active, ATP-dependent mechanism should have reduced uptake in metabolically 
depleted cells. Conversely, complexes taken into the cell via a passive mechanism, such as 
passive diffusion, are not affected by metabolic inhibition and therefore the drug should 
accumulate in inhibited and uninhibited cells at similar concentrations. [Rh(phen)(chrysi)
(PPO)]2+ and the parent metalloinsertor, [Rh(bpy)2(chrysi)]3+, were studied to determine if 
the mechanism of metalloinsertor uptake was ATP-dependent. The compounds RbCl and 
[Ru(dppz)(DIP)2]2+ were included as positive and negative controls, respectively. The 
rubidium ion of RbCl is transported into the cell by Na,K-ATPase, an ATP-dependent ion 
pump, while [Ru(dppz)(DIP)2]2+ has previously been shown to enter the cell via passive 
diffusion.27, 32 Cells were treated with each compound for 1 h before they were lysed and 
analyzed by ICP-MS for metal content. As rubidium, ruthenium, and rhodium are not 
naturally present in cells or cell culture reagents, all three elements can be analyzed as low-
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background analytes by ICP-MS. The results of each compound in HCT116O cells are 
shown in Figure 6 (results in HCT116N cells are similar and shown in Supplementary 
Figure S18). As expected, RbCl showed a significant decrease in uptake when pre-treated 
with metabolic inhibitors and [Ru(dppz)(DIP)2]2+ was unaffected by inhibitor pre-treatment. 
Similar to [Ru(dppz)(DIP)2]2+, [Rh(phen)(chrysi)(PPO)]2+ and [Rh(bpy)2(chrysi)]2+ were 
also unaffected by inhibitor pre-treatment, suggesting these complexes are also taken into 
the cell via an ATP-independent mechanism, such as passive diffusion. Since these 
complexes are all lipophilic and cationic, passive diffusion is a reasonable uptake 
mechanism, with the negative membrane potential driving diffusion and relatively high 
lipophilicity facilitating the process as the molecules can more readily partition into the 
cellular membranes.33
Subcellular localization into the nucleus (the on-target organelle) and mitochondria (a major 
off-target organelle) were also examined by an ICP-MS assay. Localization studies were 
performed with each [Rh(L)(chrysi)(PPO)]2+ metalloinsertor at 0.5 μM with the exception 
of [Rh(DIP)(chrysi)(PPO)]2+, which was performed at 0.2 μM. For localization studies, cells 
were incubated with metalloinsertors for 24 h before they were lysed and analyzed for 
rhodium content via ICP-MS, with rhodium concentrations normalized to the protein content 
of each sample. The whole cell uptakes of each metalloinsertor in HCT116O cells are shown 
in Figure 7 (results in HCT116N cells are similar and shown in Supplementary Figure S19). 
Overall, all [Rh(L)(chrysi)(PPO)]2+ complexes have comparable nuclear uptakes and 
mitochondrial uptakes to one another with the exception of [Rh(DIP)(chrysi)(PPO)]2+, 
which has nuclear and mitochondrial uptakes that are 2–3 times higher than other complexes 
despite being dosed at a lower concentration. All complexes appear to enter the nucleus at 
high enough concentrations to bind DNA mismatches, with a significant enrichment in 
nuclear concentration over the extracellular concentration of rhodium (Supplementary Table 
S1).
DISCUSSION
Early generations of rhodium metalloinsertors, which exclusively contain Rh–N ligand 
coordination, are a richly studied family of metal complexes that can selectively bind to 
DNA base pair mismatches and lead to selective cell death in MMR-deficient cells. Across 
multiple studies, these metalloinsertors were determined to have several characteristic and 
consistent behaviors. Through in vitro experiments, we have observed that only the Δ- 
enantiomer of these Rh–N coordinated complexes is capable of binding mismatches in B-
form DNA.34 In cellular studies, these metalloinsertors have been observed to selectively kill 
cells in concentration ranges of 5–40 μM.20,21 In one structure-activity relationship study, 
the steric bulk of the ancillary ligands on a metalloinsertor was seen to influence DNA 
binding properties and, ultimately, alter cellular selectivity.21 In another structure-activity 
relationship study, the lipophilicity of the ancillary ligands on a metalloinsertor was seen to 
dramatically influence its subcellular localization within a cell and, again, alter cellular 
selectivity.20
While the above trends seem to ring true across parent metalloinsertors containing 
exclusively Rh–N ligand coordination, the recent emergence of a new family of 
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metalloinsertors that contain Rh–O ligand coordination has challenged many of these 
characteristics and behaviors.19 For instance, both enantiomers of Rh–O metalloinsertors 
are capable of binding DNA mismatches in vitro, and are furthermore capable of inducing 
selective cellular toxicity at nanomolar concentrations. Additionally, changes in lipophilicity 
and steric bulk of the O-containing ligand seemed to have little, if any, effect on DNA 
binding affinity and cellular selectivity. This remarkable shift in metalloinsertor activity 
revealed that these Rh–O complexes have distinct in vitro characteristics and biological 
properties from their parent metalloinsertor complexes. As such, a new family of Rh–O 
metalloinsertors has been synthesized, characterized, and investigated for biological activity. 
In contrast to the first generation of Rh–O metalloinsertors in which the O-containing ligand 
was varied, in this new family an ancillary ligand was varied and the O-containing ligand 
was kept constant. This family is of the form [Rh(L)(chrysi)(PPO)]2+, where L = bpy, phen, 
HDPA, 4,7-DMP, 5,6-DMP, and DIP. This ligand variation influences many features of the 
metalloinsertor, including steric bulk and lipophilicity, both of which have previously been 
seen to affect DNA binding and cellular activity of the parent metalloinsertors.20,21 In 
studying this family of complexes, we aimed to test the unique biological activity of 
metalloinsertors containing the Rh–O ligand framework and begin to understand the high 
potency and improved selectivity exhibited by these metalloinsertors over parent 
metalloinsertors and other DNA-binding complexes.
Robustness of Biological Activity of the Rh–O Ligand Framework
A primary aim of this structure-activity relationship study was to determine if altering the 
ancillary ligand of Rh–O metalloinsertors would significantly affect the biological activity 
of these complexes. Biological activity was assessed through both ELISA and MTT assays 
in two cell lines, HCT116N and HCT116O. These cells are derived from the same colorectal 
carcinoma cell line but differ primarily in that HCT116N cells are MMR-proficient whereas 
HCT116O cells are MMR-deficient.35 For this reason, HCT116O cells have a higher relative 
abundance of DNA mismatches over HCT116N cells and therefore should be more sensitive 
to mismatch-targeting metalloinsertors.36
Indeed, all complexes prepared showed highly selective anti-proliferative or cytotoxic effects 
toward the MMR-deficient cells over the MMR-proficient cells in both ELISA (Figure 3) 
and MTT assays (Figure 4), with the exception of [Rh(HDPA)(chrysi)(PPO)]2+, which only 
shows activity in the ELISA. While selectivity was seen for all complexes, the effective 
concentrations varied by two orders of magnitude across the family. For instance, 
[Rh(HDPA)(chrysi)(PPO)]2+ has very low potency and little selectivity compared to other 
Rh–O metalloinsertors. Although it does appear to interfere selectively with DNA synthesis 
via ELISA, this biological interaction does not appear significant enough to produce 
cytotoxic effects in the MTT assay, even at high drug concentrations (Figure 4). HDPA is the 
only ligand containing a labile proton and the only ligand that forms a 6-ring chelate with 
the metal, and it seems possible that these structural features ultimately influence the 
biological activity of the [Rh(HDPA)(chrysi)(PPO)]2+. It is possible that the 6-member 
chelate could cause structural aberrations and the proton on HDPA could cause hydrogen-
bonding interactions that ultimately alter DNA-binding or DNA-processing by proteins, 
which could cause a decrease in toxicity. [Rh(bpy)(chrysi)(PPO)]2+ has the second lowest 
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potency of this new family, though remarkably this complex still shows higher potency than 
the parent metalloinsertors containing only Rh–N coordination.20 The phenanthroline-
derived metalloinsertors, [Rh(phen)(chrysi)(PPO)]2+, [Rh(4,7-DMP)(chrysi)(PPO)]2+, and 
[Rh(5,6-DMP)(chrysi)(PPO)]2+, all show comparable nanomolar potencies and selectivities 
in the ELISA and MTT assays.
Perhaps the most surprising biological activity is seen with [Rh(DIP)(chrysi)(PPO)]2+. 
Historically, metalloinsertors containing the bulky DIP ligand have shown no selectivity for 
the MMR-deficient cell line.21 This lack of selectivity was attributed to substantially lower 
mismatch binding affinities (104 M−1 for [Rh(DIP)2(chrysi)]3+) owing to ancillary bulk, as 
well as off-target localization into the mitochondria, a property that is common with 
lipophilic cations.20,37 [Rh(DIP)(chrysi)(PPO)]2+, however, does exhibit selective 
cytotoxicity towards MMR-deficient cells over proficient cells in both the ELISA and MTT 
assays. In fact, [Rh(DIP)(chrysi)(PPO)]2+ displays a similar selectivity and ~2-fold higher 
potency than [Rh(phen)(chrysi)(PPO)]2+ when measured by ELISA (Figure 3).
Overall, these results confirm that Rh–O metalloinsertor biological selectivity is minimally 
influenced by substitution at the ancillary ligand.19 Thus far, all of the Rh–O 
metalloinsertors, derivatized at the O-containing ligand or ancillary ligand, have exhibited 
selectivity in ELISA and/or MTT assays, regardless of steric bulk or lipophilicity, factors 
that had heavily influenced (and sometimes abolished) the selectivity of parent 
metalloinsertors. It is noteworthy that this selectivity profile, wherein the Rh–O 
metalloinsertors selectively kill MMR-deficient cells, is shared with the parent complexes 
and is in stark contrast to what is seen with all other DNA-targeting therapeutics, which 
preferentially kill MMR-proficient cells.17,18 Although parent and Rh–O metalloinsertors 
share this unique selectivity profile and have similar in vitro binding properties, suggesting 
they should interact with DNA in a similar way, the Rh–O metalloinsertors are dramatically 
more potent than the parent metalloinsertors, with nearly all Rh–O complexes (with the sole 
exception being [Rh(HDPA)(chrysi)(PPO)]2+) having greater cytotoxicity in MMR-deficient 
cells than any of the parent metalloinsertors. It stands to reason, then, that the high potency 
and selectivity of these Rh–O complexes does not reflect a difference in DNA binding 
affinity from the parent complexes, but rather it must instead reflect a difference in structure 
associated with the DNA-metalloinsertor lesion. That is, if the frequency of DNA binding is 
comparable between the Rh–O and parent metalloinsertors, the lesion formed by Rh–O 
metalloinsertors must activate a cellular response at lower concentrations.
Uptake Characteristics
Although the [Rh(L)(chrysi)(PPO)]2+ family shows consistent activity towards MMR-
deficient cells, the selectivities and potencies of these complexes vary significantly across 
the family from 160 nM to 25 μM. It was initially hypothesized that these differences in 
biological activity could be due to differences in cellular uptake. In particular, it seemed 
possible that the least potent complexes, [Rh(HDPA)(chrysi)(PPO)]2+ (which has almost no 
cytotoxic properties at 40 μM) and [Rh(bpy)(chrysi)(PPO)]2+ (which has nearly 10-fold 
lower potency than [Rh(phen)(chrysi)(PPO)]2+), could be less effective due to low uptake. 
Similarly, it was proposed that increased uptake could be responsible for the high potency of 
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[Rh(DIP)(chrysi)(PPO)]2+. Indeed, it does seem possible that uptake may explain some of 
the observed potency trends: despite being dosed at 0.2 μM, [Rh(DIP)(chrysi)(PPO)]2+ 
exhibits similar uptake to [Rh(phen)(chrysi)(PPO)]2+, which was dosed at 0.5 μM. The 
finding suggests that [Rh(DIP)(chrysi)(PPO)]2+ may induce biological effects at half the 
concentration of [Rh(phen)(chrysi)(PPO)]2+ as a result of complexes exhibiting similar 
uptakes at these concentrations. However, uptake alone appears insufficient to explain the 
potencies of other complexes. For instance, [Rh(HDPA)(chrysi)(PPO)]2+ and [Rh(bpy)
(chrysi)(PPO)]2+ have comparably low uptake into the cell despite a >10-fold difference in 
activity.
Organelle-specific uptake is also worthy of consideration when examining the activity of 
these complexes. Studies on previous generations of parent metalloinsertors bearing solely 
Rh–N ligand coordination showed that off-target mitochondrial uptake is strongly influenced 
by ligand lipophilicity, with the most lipophilic parent metalloinsertors having high 
mitochondrial uptake and low selectivity for MMR-deficient cells.20,38 Surprisingly, all Rh–
O metalloinsertors studied here are more lipophilic than any of the parent metalloinsertors 
described above, yet all Rh–O complexes exhibit selective cytotoxicity towards MMR-
deficient cells, making their selectivity patterns distinct from trends followed by the parent 
metalloinsertors. To better understand this marked change in trends, on-target nuclear 
localization and off-target mitochondrial localization experiments were performed to assess 
the biological activity of [Rh(L)(chrysi)(PPO)]+2 complexes, particularly DIP, which shows 
selectivity despite its very high lipophilicity.
As indicated, all [Rh(L)(chrysi)(PPO)]2+ metalloinsertors enter the nuclei to a similar extent 
and at high enough concentrations to bind DNA mismatches (Figure 7 and Supplementary 
Table S1). Similarly, all [Rh(L)(chrysi)(PPO)]2+ metalloinsertors enter the mitochondria to a 
comparable extent. Although nuclear and mitochondrial uptake cannot be compared directly 
(since each is normalized to the total protein in the organelle), the localization patterns of 
Rh–O versus parent metalloinsertors can be compared (See Supplementary Figure S20). 
This comparison shows that, unlike their Rh–N coordinated predecessors, Rh–O 
metalloinsertor localization into the mitochondria is not significantly influenced by 
lipophilicity. In fact, despite being lipophilic, Rh–O complexes exhibit uptake profiles that 
are comparable to hydrophilic parent metalloinsertors (which have low mitochondrial 
uptake) and are distinct from lipophilic parent metalloinsertors (which have high 
mitochondrial uptake). This trend in localization is consistent with the biological activity we 
observed; similar to the hydrophilic parent metalloinsertors, Rh–O complexes are highly 
selective and show little off-target cytotoxicity. Overall, these data indicate that Rh–O 
metalloinsertors are able to maintain their high selectivity and potency because the ligand 
substitutions do not strongly influence their subcellular localization. Since these complexes 
exhibit low mitochondrial uptake, off-target mitochondria-induced toxicity does not 
overwhelm the biological response, and the selective nuclear- and mismatch-mediated 
response can prevail.
It is also interesting to note that both MMR-proficient HCT116N cells and MMR-deficient 
HCT116O cells had comparable levels of uptake and similar localization profiles, showing 
that metalloinsertors enter HCT116N and HCT116O cells at the same rate, through the same 
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passive mechanism, and to the same extent (Figure 5 and 6 and Supplementary Figures S17 
and S18). These details support the idea that the biological selectivity seen in these cells is 
not a feature of different cellular uptake or elimination properties. Furthermore, the nuclear 
uptake into the MMR-deficient and proficient cells are comparable (Figure 7 and 
Supplementary Figure S19). Therefore, with similar concentrations of metalloinsertors 
entering the nuclei and similar mismatch binding affinities, any DNA-mediated cytotoxicity 
must result from a difference in how the drugs interact with the DNA. Rationally, this 
difference must depend upon an increased mismatch targeting in MMR-deficient cells, 
where DNA base pair mismatches are more abundant.36
Source of Potency for the Rh–O Metalloinsertors
Although MMR-deficient cells have a relative abundance of mismatches compared to MMR-
proficient cells, the total number of mismatches formed during each cellular replication is 
ultimately small due to the high fidelity and proofreading abilities of polymerases. It is clear, 
therefore, that the lesion formed by parent metalloinsertors must be significantly potent such 
that even a small number of metalloinsertor-DNA lesions can result in selective cell death. 
Moreover, despite their similar mismatch binding affinities, the Rh–O metalloinsertors are 
even more potent than parent metalloinsertors, and therefore these Rh–O metalloinsertors 
must produce a unique lesion structure at the mismatched site that can activate a response at 
even lower concentrations (and therefore fewer metalloinsertor-DNA lesions) than parent 
metalloinsertors.
Does the increase in potency depend upon a difference in how these Rh–O metalloinsertors 
bind to DNA within the cell?19 As discussed above, both the Δ- and Λ-enantiomers of 
[Rh(phen)(chrysi)(PPO)]2+ can bind to DNA mismatches in vitro and selectively kill MMR-
deficient cells in culture. This behavior is distinct from parent metalloinsertors, for which 
only the Δ-enantiomer can bind mismatches and produce biological effects.15 The ability of 
both enantiomers of Rh–O metalloinsertors to bind mismatched DNA suggests the binding 
interaction must be fundamentally distinct from that of the parent metalloinsertors; these 
new Rh–O metalloinsertors must bind DNA in a way that can accommodate the Λ-
enantiomer.
Furthermore, some evidence suggests that even the DNA-binding ability of the Δ-enantiomer 
may be altered in these Rh–O metalloinsertors. Previously, it was observed that bulky parent 
metalloinsertors, such as [Rh(DIP)2(chrysi)]3+, exhibited poor binding affinities (104 M−1) 
and could not easily be modeled to fit into a mismatched DNA lesion due to significant 
steric clashing between the DIP ligands and the DNA backbone.21 In contrast, significant 
differences in ancillary ligand steric bulk have minimal effect on the binding affinities of 
Rh–O metalloinsertors, which all bind to DNA with micromolar affinity. Even the most 
sterically bulky complex, [Rh(DIP)(chrysi)(PPO)]2+, has a relatively high affinity for 
mismatched DNA (106 M−1) despite containing the bulky DIP ligand. It therefore seems that 
the inclusion of the DIP ligand is not sufficient to preclude DNA binding, and perhaps this 
dramatic increase in binding affinity of a DIP-containing metalloinsertor may indicate that a 
new binding interaction exists that can accommodate the steric bulk of these Rh–O 
metalloinsertors.
Boyle and Barton Page 19
J Am Chem Soc. Author manuscript; available in PMC 2018 May 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Another consideration is the conformation of the chrysi ligand of these new Rh–O 
metalloinsertors. All Rh–O complexes have chrysi imine pKa values above physiological 
pH, indicating that they remain protonated in the intracellular environment. This protonation 
results in steric clashing between the imine proton and an aromatic proton in the chrysi 
system and, as a result, the chrysi ligand becomes buckled relative to the rhodium center to 
relieve the steric strain.19 This is in stark contrast to parent metalloinsertors which 
deprotonate at cellular pH and therefore do not exhibit steric clashing between the imine and 
aromatic protons. As a result, the chrysi ligand lays planar in these parent metalloinsertors. 
Distortion of the chrysi ligand, the ligand that interacts most intimately with the DNA, likely 
disrupts the overall metalloinsertor-DNA binding interaction, further suggesting there is 
likely a difference in how Rh–O and parent metalloinsertors bind to DNA.19
Lastly, the Rh–O complexes reported here are lipophilic (log P > 0), whereas comparable 
parent metalloinsertors are hydrophilic (log P < 0).38 This change in lipophilicity could alter 
the way Rh–O complexes interact with the hydrophobic bases of DNA or even DNA-
processing proteins that may be responsible for recognizing the DNA-metalloinsertor lesion. 
Overall, these results suggest that the Rh–O metalloinsertors bind to DNA differently than 
parent metalloinsertors. While these complexes still appear to undergo metalloinsertion, as 
evidenced by their ability to bind mismatched DNA with high affinity, it is unclear how their 
binding might be distinct from parent metalloinsertors. It seems possible that a subtle 
difference in the extent or orientation of mismatched base ejection or in the unwinding of the 
DNA helix by the metalloinsertor could ultimately result in a difference in how that lesion is 
recognized or processed within the cell, which could lead to overall cellular response and 
increased potency. Crystallographic studies of Rh–O metalloinsertors with DNA are 
currently underway to investigate the potential difference between parent and Rh–O 
metalloinsertor binding.
Implications for Future Metalloinsertor Design
The [Rh(L)(chrysi)(PPO)]2+ family of metalloinsertors described herein display biological 
selectivity and potency that are maintained across various ligand frameworks varying in size 
and lipophilicity. When compared with other Rh–O metalloinsertors in which the PPO-type 
ligand is varied, metalloinsertors containing the Rh–O motif are consistent in their 
biological selectivity (and, to a large extent, potency) for MMR-deficient cells regardless of 
significant alterations to their ancillary ligands. It has previously been shown that the 
metalloinsertors with DIP ligands and PPO-type ligands cannot be easily modeled into a 
mismatched DNA lesion due to steric clashes with the DNA structure.19,21 Despite steric 
bulk, Rh–O metalloinsertors have comparable binding affinities to parent metalloinsertors 
and significantly improved biological activity. Furthermore, these complexes show little 
enantioselectivity; both isomers bind DNA and show high potency, further supporting that 
their metalloinsertion binding interaction markedly differs from parent metalloinsertors. 
Taken together, these observations show that the Rh–O metalloinsertor framework has great 
potential for the design of new therapeutics and for the attachment of new payloads, while 
maintaining biological selectivity.39–43 The consistently high potency and cell selectivity of 
these complexes is unique and provides the basis for new generations of metalloinsertors and 
metalloinsertor conjugates.
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Figure 1. 
General structure of the newest generation of Rh−O metalloinsertors (left), which show 
improved potency and selectivity over parent metalloinsertors that have exclusively Rh–N 
coordination (right). R has been varied between methyl, phenyl, pyridyl, and hexyl groups 
and N—N has been varied between several bpy, phen, and HDPA derivatives.
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Figure 2. 
Chemical structures of [Rh(L)(chrysi)(PPO)]2+ family of rhodium metalloinsertors, with the 
PPO ligand shown in red and the changing ancillary ligand shown in blue.
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Figure 3. 
Cellular proliferation ELISA for the [Rh(L)(chrysi)(PPO)]2+ metalloinsertors in MMR-
deficient (HCT116O, red circles) and MMR-proficient (HCT116N, blue squares) cells. Cells 
were incubated with various concentrations of metalloinsertor for 48 h before treatment with 
BrdU. Cell proliferation is shown as %BrdU incorporated into DNA compared to untreated 
control cells. Error is shown as the standard deviation of 5 replicates.
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Figure 4. 
Cellular viability MTT assay for the [Rh(L)(chrysi)(PPO)]2+ metalloinsertors in MMR-
deficient (HCT116O, red circles) and MMR-proficient (HCT116N, blue squares) cells. Cells 
were incubated with various concentrations of metalloinsertor for 72 h before treatment with 
MTT. Cell proliferation is shown as % viability from MTT metabolism, compared to 
untreated control cells. Error is shown as the standard deviation of 5 replicates.
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Figure 5. 
Whole-cell rhodium uptake assays. (left) Rhodium accumulation in HCT116O was 
measured by ICP-MS analysis after a 24 hour incubation with [Rh(L)(chrysi)(PPO)]2+ 
metalloinsertors (where L = phen, bpy, HDPA, 4,7-DMP, 5,6-DMP, or DIP). (right) 
Rhodium accumulation over time in HCT116O cells was measured by ICP-MS for three 
metalloinsertors, [Rh(phen)(chrysi)(PPO)]2+ (phen), [Rh(DIP)(chrysi)(PPO)]2+ (DIP), and 
the parent metalloinsertor [Rh(bpy)2(chrysi)]3+ (Rh-BC). Rhodium content was normalized 
to protein content determined by BCA assay, and the results of four independent trials were 
averaged with error shown as the standard deviation.
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Figure 6. 
Uptake assay for rhodium metalloinsertors and controls. [Rh(phen)(chrysi)(PPO)]2+ (phen), 
[Rh(bpy)2(chrysi)]3+ (Rh-BC), [Ru(DIP)2(chrysi)]2+ (Ru- DIP), and RbCl accumulation in 
HCT116O cells was measured by ICP-MS analysis after treatment with or without 
metabolic inhibitors (oligomycin and 2-deoxy-D-glucose). Rhodium, ruthenium, and 
rubidium contents were normalized to protein content determined by BCA assay. Each 
experiment was performed in triplicate and averaged, with error shown as the standard 
deviation. Each experiment was repeated three times with similar outcomes (not shown). 
RbCl* indicates that Rb concentrations for RbCl have been lowered by a factor of 500 in 
this graphic.
Boyle and Barton Page 28
J Am Chem Soc. Author manuscript; available in PMC 2018 May 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. 
ICP-MS assay for nuclear and mitochondrial uptake of rhodium metalloinsertors. Rhodium 
accumulation in HCT116O cells was measured by ICP-MS analysis after a 24 hour 
incubation with [Rh(L)(chrysi)(PPO)]2+ (where L = phen, bpy, HDPA, 4,7-DMP, 5,6-
DMP or DIP). Rhodium content was normalized to protein content of each organelle 
fraction determined by BCA assay. The results of 4 independent studies were averaged with 
error shown as the standard deviation.
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Table 1
Binding affinity, pKa, and Log P values for each metalloinsertor
Metalloinsertor Binding Constant (× 106 M−1)a pKa (2+ to 1+) Log P
Δ-[Rh(phen)(chrysi)(PPO)]2+ 6.6 – –
Λ-[Rh(phen)(chrysi)(PPO)]2+ 9.2 – –
rac-[Rh(phen)(chrysi)(PPO)]2+ 5.5b 8.3 ± 0.3a 1.4 ± 0.1
rac-[Rh(bpy)(chrysi)(PPO)]2+ 7.2 8.9 ± 0.1 0.68 ± 0.07
rac-[Rh(HDPA)(chrysi)(PPO)]2+ 3.0 9.1 ± 0.1 0.69 ± 0.08
rac-[Rh(4,7-DMP)(chrysi)(PPO)]2+ 1.5 9.1 ± 0.1 1.1 ± 0.1
rac-Rh[(5,6-DMP)(chrysi)(PPO)]2+ 2.3 9.0 ± 0.3 0.71 ± 0.01
rac-[Rh(DIP)(chrysi)(PPO)]2+ 1.6 8.1 ± 0.1 > 2.0c
abinding affinities measured using the DNA hairpin 5′-GGCAGGCATGGCTTTTTGCCATCCCTGCC-3′ (underline denotes mismatch) in 100 
mM NaCl, 20 mM NaPi, pH 7.1 buffer. Competition titrations were performed against the photocleaving metalloinsertor [Rh(bpy)2(chrysi)]Cl3.
bValues from reference 19
c
The change in absorbance in the [Rh(DIP)(chrysi)(PPO)]2+-containing 1-octanol phase before and after equilibration with the aqueous phase was 
too small to accurately and consistently measure.
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